​Frontage has developed a next-generation sequencing (NGS)-based method to rapidly determine the genotype of 300+ genes involved in ADME, called the Frontage PGx NGS Test.

Oligonucleotide (OGN) therapy is increasingly recognized as an important therapeutic modality with the promise of curing diseases. However, unlike most biotherapeutics, the development of OGN drugs often requires their determination with high sensitivity and specificity in multiple, complex biologic matrices such as blood and tissues in order to measure their exposure and distribution for understating PK, PD, and safety.

At Frontage Laboratories (PA, USA), we have developed highly sensitive and specific quantitative methods for the determination of OGN in plasma and tissues using hybridization immunoassay and LC–MS techniques. In this webinar, we will present the method development, validation, and comparison of these techniques for the quantification of OGN as well as a case study with antisense OGN.

In this case study, Frontage successfully completes the method development and validation under the Sponsor's pressing timelines, while providing high quality, and reproducible data with an ISR passing rate of over 90%.